The advanced, metastatic differentiated thyroid cancers (DTCs) have a poor prognosis
mainly owing to radioactive iodine (RAI) refractoriness caused by decreased expression of …

Recurrent, metastatic disease represents the most frequent cause of death for patients with
thyroid cancer, and radioactive iodine (RAI) remains a mainstay of therapy for these patients …

Expression of the sodium iodide symporter (NIS) is required for efficient iodide uptake in
thyroid and lactating breast. Since most differentiated thyroid cancer expresses NIS, β …

Thyroid cancer is the most prevalent endocrine tumor and its incidence is fast-growing
worldwide in recent years. Differentiated thyroid cancer (DTC) is the most common …

The management of radioiodine refractory thyroid cancers (RAIR TC) is challenging for the
clinician. Tyrosine kinase inhibitors classically prescribed in this setting can fail due to …

The sodium iodide symporter (NIS) is an intrinsic plasma membrane protein that mediates
active iodide transport into the thyroid gland and into several extrathyroidal tissues. NIS …

Approximately 30% of patients with advanced, metastatic differentiated thyroid cancer have
radioiodine-refractory disease, based on decreased expression of the sodium iodide …

Based on experimental data, the inhibition of the MAPkinase pathway in patients with
radioiodine-refractory thyroid cancer was capable of inducing a redifferentiation. Preliminary …

Pediatric papillary thyroid carcinoma (PPTC) is clinically distinct from adult-onset disease.
Although there are higher rates of metastasis and recurrence in PPTC, prognosis remains …

Purpose: Patients with aggressive thyroid cancer are frequently failed by the central therapy
of ablative radioiodide (RAI) uptake, due to reduced plasma membrane (PM) localization of …